Drug companies accused of stalling tailored therapies

Companies are reluctant to limit their market share, report says.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Author information

Related links

Related links

Related links in Nature Research

Lack of data privacy could hamper pharmacogenomics studies

Royal Society puts personalized medicine in perspective

Looking for solid ground along the Critical Path

FDA pharmacogenomics guidance sends clear message to industry

Related external links

FDA guidelines

Pharmacogenetics Study Group report

Rights and permissions

Reprints and Permissions

About this article

Further reading